Compare ICUI & GBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ICUI | GBDC |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 1992 | 2010 |
| Metric | ICUI | GBDC |
|---|---|---|
| Price | $154.43 | $12.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $179.50 | $14.17 |
| AVG Volume (30 Days) | 245.2K | ★ 2.4M |
| Earning Date | 02-19-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 12.43% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.24 |
| Revenue | ★ $2,320,363,000.00 | $857,084,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.09 |
| Revenue Growth | N/A | ★ 9.80 |
| 52 Week Low | $107.00 | $12.28 |
| 52 Week High | $165.17 | $16.01 |
| Indicator | ICUI | GBDC |
|---|---|---|
| Relative Strength Index (RSI) | 54.98 | 29.77 |
| Support Level | $148.71 | $12.28 |
| Resistance Level | $155.60 | $13.08 |
| Average True Range (ATR) | 4.36 | 0.24 |
| MACD | -0.47 | -0.13 |
| Stochastic Oscillator | 41.70 | 10.63 |
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
Golub Capital BDC Inc. is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and capital appreciation by investing in senior secured and one-stop loans in U.S. middle-market companies. It also invests in second-lien and subordinated loans, warrants, and minority equity securities in U.S. middle-market companies. The company generally invests in securities rated below investment grade by independent rating agencies, or those that would be rated below investment grade if evaluated. The company operates in the USA, Canada, and other countries, with the majority of its revenue coming from the USA.